[ad_1]
AstraZeneca said initial deliveries to the European Union of the Covid-19 vaccine it is developing with the University of Oxford will not reach the targeted volumes due to a production issue.
“Initial volumes will be lower than originally forecast due to reduced yields at a manufacturing site within our European supply chain,” a company spokesperson said in a written statement, declining to provide details.
“We will deliver tens of millions of doses in February and March to the European Union, as we continue to increase production volumes,” he added. It would not provide the initial volume target.
A decision on the compound’s EU regulatory approval is expected in late January.
AstraZeneca said there would be no expected delay in starting shipments of its vaccine to Europe if it received EU approval. – Reuters
Source link
